[미국특허]
Capping bioprosthetic tissue to reduce calcification
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-002/00
A61L-027/36
A61L-027/50
A61F-002/24
출원번호
US-0139367
(2013-12-23)
등록번호
US-9029418
(2015-05-12)
발명자
/ 주소
Dove, Jeffrey S.
Dobler, Darin P.
Davidson, James A.
Wright, Gregory A.
출원인 / 주소
Edwards Lifesciences Corporation
대리인 / 주소
Kaiser, AnneMarie
인용정보
피인용 횟수 :
26인용 특허 :
242
초록▼
A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the meth
A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
대표청구항▼
1. A method for mitigating calcification in a bioprosthetic tissue, the method comprising: at least partially cross-linking the bioprosthetic tissue;treating the bioprosthetic tissue with a capping agent, wherein the capping agent reacts with functional groups associated with the bioprosthetic tissu
1. A method for mitigating calcification in a bioprosthetic tissue, the method comprising: at least partially cross-linking the bioprosthetic tissue;treating the bioprosthetic tissue with a capping agent, wherein the capping agent reacts with functional groups associated with the bioprosthetic tissue; andtreating the bioprosthetic tissue with a reducing agent, wherein the reducing agent reduces any Schiff bases created by the reaction of the capping agent and the functional groups associated with the bioprosthetic tissue. 2. The method of claim 1, wherein the bioprosthetic tissue is selected from the group consisting of bovine pericardium, porcine tissue, blood vessel, skin, dura mater, pericardium, small intestinal submucosa, tissue heart valve, ligaments, and tendon. 3. The method of claim 1, wherein the at least partially cross-linking the bioprosthetic tissue is performed with glutaraldehyde or other aldehyde-containing agents. 4. The method of claim 1, wherein the treating steps are performed after the at least partially cross-linking step and wherein the functional groups are associated with the at least partially cross-linked bioprosthetic tissue. 5. The method of claim 1, wherein the functional groups are associated with in vivo toxicity, calcification, and immunogenicity of the bioprosthetic tissue. 6. The method of claim 5, wherein the functional groups are one or both of an aldehyde group and a carboxylic acid group. 7. The method of claim 1, wherein the capping agent is one or more selected from the group consisting of: an amine, an alkyl amine, an amino alcohol, an ethanolamine, an amino acid, a lysine, a hydroxylysine, an amino sulfonate, a taurine, an amino sulfate, a dextran sulfate, a chondroitin sulfate, a hydrophilic multifunctional polymer, a polyvinyl alcohol, a polyethyleneimine, a hydrophobic multifunctional polymer, an α-dicarbonyl, a methylglyoxal, a 3-deoxyglucose, a glyoxal, a hydrazide, an adipic hydrazide, a heparin, a mono-epoxy alkane, a di-epoxy alkane, and a polyepoxyalkane. 8. The method of claim 1, wherein the reducing agent is selected from the group consisting of: a sodium borohydride and a sodium cyanoborohydride. 9. The method of claim 1, further comprising one of dehydrating the at least partially-crosslinked tissue or treating the at least partially cross-linked bioprosthetic tissue with a glycerol solution. 10. The method of claim 9, further comprising packaging the at least partially cross-linked bioprosthetic tissue after dehydrating or treating with the glycerol solution. 11. The method of claim 10, further comprising sterilizing the packaged, at least partially cross-linked bioprosthetic tissue. 12. The method of claim 11, wherein the sterilizing is performed by ethylene oxide, gamma irradiation, or electron beam irradiation. 13. A bioprosthetic heart valve comprising the bioprosthetic implant tissue treated in accordance with claim 1. 14. A method for mitigating calcification in a biological tissue, the method comprising: at least partially cross-linking the bioprosthetic tissue with glutaraldehyde or other aldehyde-containing agents; andexposing the cross-linked bioprosthetic tissue to a capping agent, the capping agent being one or a combination selected from the group consisting of: an amino alcohol, an ethanolamine, an amino acid, a lysine, a hydroxylysine, an amino sulfonate, a taurine, an amino sulfate, a dextran sulfate, a chondroitin sulfate, a polyvinyl alcohol, an α-dicarbonyl, a methylglyoxal, a 3-deoxyglucosone, a glyoxal, a hydrazide, an adipic hydrazide, a heparin, a mono-epoxy alkane, a di-epoxy alkane, and a polyepoxy alkane. 15. The method of claim 14, wherein the bioprosthetic tissue is selected from the group consisting of bovine pericardium, porcine tissue, blood vessel, skin, dura mater, pericardium, small intestinal submucosa, tissue heart valve, ligaments, and tendon. 16. The method of claim 14, wherein the exposing steps are performed after the at least partially cross-linking step and wherein the functional groups are associated with the at least partially cross-linked bioprosthetic tissue. 17. The method of claim 14, wherein the capping agent is ethanolamine. 18. The method of claim 14, wherein the capping agent is taurine. 19. The method of claim 14, wherein the capping agent is provided in one or a combination of an aqueous solution, an organic solvent and an organic buffered solution. 20. The method of claim 19, wherein the aqueous solution is selected from the group consisting of: a buffered solution, water, short chain alcohols, glycerol, and a plasticizer. 21. The method of claim 14, further comprising exposing the bioprosthetic tissue to a reducing agent simultaneously with or after the step of exposing the bioprosthetic tissue to the capping agent. 22. The method of claim 21, wherein the reducing agent is selected from the group consisting of: a sodium borohydride and a sodium cyanoborohydride. 23. The method of claim 14, further comprising one of dehydrating the at least partially cross-linked bioprosthetic tissue or treating the at least partially cross-linked bioprosthetic tissue with a glycerol solution. 24. The method of claim 23, further comprising packaging the at least partially cross-linked bioprosthetic tissue after the dehydrating or treating with the glycerol solution. 25. The method of claim 24, further comprising sterilizing the packaged, at least partially cross-linked bioprosthetic tissue. 26. The method of claim 25, wherein the sterilizing is performed by ethylene oxide, gamma irradiation, or electron beam irradiation. 27. A bioprosthetic heart valve comprising the bioprosthetic implant tissue treated in accordance with claim 14. 28. A method for mitigating calcification in a bioprosthetic tissue, the method comprising: at least partially cross-linking the bioprosthetic tissue; andtreating the bioprosthetic tissue with a capping agent solution to react with carboxylic acid functional groups associated with the bioprosthetic tissue, the capping agent solution comprising an amine in combination with one or more of N,N-disuccinimidyl carbonate, carbodiimides, 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide, N-cyclohexyl-N′-(2-morpholinoethyl)carbodiimide, 1,3-dicyclohexyl carbodiimide, 2-chloro-1-methylpyridium iodide, and N-hydroxysulfosuccinimide. 29. The method of claim 28, wherein the capping agent solution comprises ethanolamine, 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride and N-hydroxysulfo succinimide. 30. A bioprosthetic heart valve comprising the bioprosthetic implant tissue treated in accordance with claim 28. 31. The method of claim 1, wherein the reducing agent is selected from the group consisting of: a sodium bisulfite in acetylacetone and formic acid in formaldehyde. 32. The method of claim 14, wherein the reducing agent is selected from the group consisting of: a sodium bisulfite in acetylacetone and formic acid in formaldehyde. 33. The method of claim 1, wherein the capping agent is one or more selected from the group consisting of; a hydroxylysine, a taurine, a dextran sulfate, a chondroitin sulfate, a polyvinyl alcohol, an a-dicarbonyl, the methylglyoxal, a 3-deoxyglucosonc, a glyoxal, a hydrazide, an adipic hydrazide, a heparin, a mono-epoxy alkanel, a di-epoxy alkane, and a polyepoxy alkane. 34. The method of claim 14, wherein the capping agent is one or more selected from the group consisting of; the hydroxy lysine, the taurine, the dextran sulfate, the chondroitin sulfate, the polyvinyl alcohol, the a-dicarbonyl, the methylglyoxal, the 3-deoxyglucosone, the glyoxal, the hydroxide, the adipic hydrazide, the heparin, the mono-epoxy Alkane, the di-cpoxy alkane, and the polyepoxy alkane.
Badejo, Ibraheem T.; Ayarza, Jaime; Voiers, Anthony; Thompson, Jr., Roy F.; Szabo, Gabriel N.; Toni, Robert V.; Nicholson, William S. C., Antioxidant enriched adhesive compositions and storage containers therefor.
Pietsch Hanns (Hamburg DEX) Kartheus Holger (Hamburg DEX) Holtzmann Hans-Joachim (Hamburg DEX) Sachau Gnther (Quickborn DEX) Reul Helmut (Dren DEX), Antithrombogenic, non-calcifying material and method of making articles for medical purposes.
Pietsch Hanns (Hamburg DEX) Kartheus Holger (Hamburg DEX) Holtzmann Hans-Joachim (Hamburg DEX) Sachau Gnther (Quickborn DEX) Reul Helmut (Dren DEX), Antithrombogenic, non-calcifying material and method of making articles for medical purposes.
Carpentier Sophie,FRX ; Carpentier Alain F.,FRX ; Quintero Lillian J. ; Packham Victor S. ; Wang Jong H. ; Schreck Stefan G., Apparatuses for treating biological tissue to mitigate calcification.
Kim Young Ha (Seoul KRX) Park Ki Dong (Seoul KRX) Han Dong Keun (Seoul KRX) Kim Hack Joo (Seoul KRX), Bioprosthetic heart valves having high calcification resistance.
Levy Robert J. (Ann Arbor MI) Sintov Amnon (Jerusalem ILX), Calcification-resistant materials and methods of making same through use of multivalent cations.
Levy Robert J. (Ann Arbor MI) Sintov Amnon (Omer ILX), Calcification-resistant materials and methods of making same through use of multivalent cations.
Levy Robert J. (Ann Arbor MI) Sintov Amnon (Ann Arbor MI), Calcification-resistant materials and methods of making same through use of trivalent aluminum.
Abraham Ginger A. ; Carr ; Jr. Robert M. ; Kemp Paul D.,GBX ; Mercer Ryan ; Baker Linda, Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix.
Heyninck-Jantz, Christine; Taitague, Debra; McNatt, Tomas R., Composite heart valve apparatus manufactured using techniques involving laser machining of tissue.
Linner John G. (Woodlands TX) Livesey Stephen A. (Woodlands TX) Piunno Carmen (Woodlands TX) Zaltsberg Mark (Woodlands TX) Gibson Frank (Spring TX), Cryo-slammer.
Keogh James R. (1201 Frank Ct. Maplewood MN 55109) Pearson David A. (7717 Beard Ave. North Brooklyn Park MN 55443) Eaton John W. (76 Bulson Rd. Troy NY 12180), Fixed tissue medical devices comprising albumin-binding dyes.
Oliver Roy F. (The University of Dundee ; Department of Biological Sciences ; The University Dundee DD1 4HN GB3) Grant Roy A. (Willow Wood ; 24 Harbour View Road Parkstone ; Dorset BH14 OPE GB3), Implant tissue.
Carpentier Alain (Paris FRX) Carpentier Sophie (Paris CA FRX) Nashef Aws S. (Costa Mesa CA), Implantable biological tissue and process for preparation thereof.
Carpentier Alain (Paris FRX) Carpentier Sophie (Paris CA FRX) Nashef Aws S. (Costa Mesa CA), Implantable biological tissue and process for preparation thereof.
McNally Robert T. (Marietta GA) McCaa Cameron (Marietta GA) Brockbank Kelvin G. M. (Marietta GA) Heacox Albert E. (Marietta GA) Bank Harvey L. (Charleston SC), Kit for cryopreserving blood vessels.
Ogle Matthew F. ; Holmberg William R. ; Schroeder Richard F. ; Guzik Donald S. ; Mirsch ; II M. William ; Bergman Darrin J. ; Finucane Hallie A. ; Tweden Katherine S., Medical article with adhered antimicrobial metal.
Piunno Carmen (The Woodlands TX) Livesey Stephen (Victoria TX AUX) Linner John G. (The Woodlands TX) del Campo Anthony A. (Houston TX) Zaltzberg Mark J. (The Woodlands TX), Method and apparatus for cryopreparing biological tissue.
Davis Dale R. (Poway CA) Klein Michael (La Mesa CA) de Larra Carcedo Carlos Miranda (Barcelona ESX) Mueller Bruce (Escondido CA) Martinez Ramon-Bartolome Pastor (Barcelona ESX) Raychoudhury Rana (Bar, Method for alleviating marangoni flow-induced print defects in ink-jet printing.
Carpentier, Alain F.; Carpentier, Sophie; Cunanan, Crystal M.; Quintero, Lillian; Helmus, Michael N.; Loshbaugh, Christine; Sarner, H. Chris, Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby.
Cunanan Crystal M. ; Quintero Lillian ; Helmus Michael N. ; Loshbaugh Christine ; Sarner H. Chris, Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby.
Livesey Stephen A. (Eltham TX AUX) del Campo Anthony A. (Houston TX) Nag Abhijit (Houston TX) Nichols Ken B. (The Woodlands TX) Coleman Christopher (Houston TX), Method for processing and preserving collagen-based tissues for transplantation.
Carpentier,Alain F.; Carpentier,Sophie; Cunanan,Crystal M.; Quintero,Lillian J.; Helmus,Michael N.; Loshbaugh,Christine; Sarner,H. Chris, Method for treatment of biological tissues to mitigate post-implantation calcification and thrombosis.
Jansen Josef (Mauerstr. 108 5100 Aachen DEX) Reul Helmut (Akazienstr. 65 5160 Duren DEX) Rau Gunter (Fuchserde 50 5100 Aachen DEX), Method of producing a closing member having flexible closing elements, especially a heart valve.
Carpentier Sophie,FRX ; Carpentier Alain F.,FRX ; Quintero Lillian J. ; Packham Victor S. ; Wang Jong H. ; Schreck Stefan G., Methods and apparatuses for treating biological tissue to mitigate calcification.
Arru Pietro (Turin ITX) Bona Gioacchino (Turin ITX) Curcio Maria (Saluggia ITX) Vallana Franco (Turin ITX), Methods for manufacture of valve flaps for cardiac valve prostheses.
MacPhee, Martin; Calvert, Glenn; Lynch, Tom; Kent, Randall S.; Mann, David; Burgess, Wilson; Miekka, Shirley; Drohan, William N., Methods for sterilizing biological materials by irradiation over a temperature gradient.
Carpentier, Sophie M.; Carpentier, Alain F., Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods.
Colvin Stephen ; Grossi Eugene ; Katz Allan ; Oddo Paul, Passive knotless suture terminator for use in minimally invasive surgery and to facilitate standard tissue securing.
Wolfinbarger ; Jr. Lloyd, Process and composition for cleaning soft tissue grafts optionally attached to bone and soft tissue and bone grafts produced thereby.
Petite Herv (118 Avenue Saint-Exupry 69500 Bron FRX) Menasche Philippe (1 rue du Regard 75006 Paris FRX) Huc Alain (26 Chemin des Fonds 69110 Sainte Foy Les Lyon FRX), Process for crosslinking of collagen by introduction of azide groups as well as tissues and biomaterials obtained by use.
Wolfinbarger, Jr., Lloyd; Lange, Perry; Linhurst, Alyce; Moore, Eric; Nolf, Barry, Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced.
Wolfinbarger, Jr.,Lloyd; Lange,Perry; Linhurst Jones,Alyce; Moore,Eric; Nolf,Barry, Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced.
Hendriks Marc,NLX ; Michel Verhoeven,NLX ; Cahalan Patrick,NLX ; Torrianni Mark W. ; Cahalan Linda,NLX ; Fouache Benedicte,FRX, Process for making a bioprosthetic device.
Hendriks Marc,NLX ; Verhoeven Michel,NLX ; Cahalan Patrick,NLX ; Zeeman Raymond,NLX ; Dijkstra Piet,NLX ; Feijen Jan,NLX, Process for making a bioprosthetic device and implants produced therefrom.
Glowczewskie ; Jr. Frank P. (Gainesville IL) Present David A. (New York NY) Anderson David W. (New York NY) McBrayer Patrick A. (Yardley PA), Reconstitution of human bone and tissue.
Roser, Bruce J.; Colaco, Camilo; Jerrow, Mohammed A. Z.; Blair, Julian; Kampinga, Jaap; Wardell, James Lewis; Duffy, John Alistair, Solid delivery systems for controlled release of molecules incorporated therein and methods of making same.
Phillips Richard E. (San Marcos TX) Moore Mark A. (Austin TX) Russell Ruth L. (Long Beach CA) Cheung David (Arcadia CA), Sterilization of tissue implants using iodine.
Hamby, Joseph; Walsh, Steven; Heacox, Al; Goldstein, Steven; Gale, David; Arnold, Stacy; Updegrove, Ann Sands, Tissue implants for implantation and methods for preparing the same.
Neev Joseph ; Da Silva Luiz B. ; Matthews Dennis L. ; Glinsky Michael E. ; Stuart Brent C. ; Perry Michael D. ; Feit Michael D. ; Rubenchik Alexander M., Ultrashort pulse high repetition rate laser system for biological tissue processing.
Mirsch ; II M. William ; Schroeder Richard F. ; Illingworth Barbara ; Borner William H. ; Montoya Susan I., Use of microorganisms for decellularizing bioprosthetic tissue.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.